About The Study: In this cross-sectional study of 60 new therapeutic agents approved by the Food and Drug Administration from 2009 to 2018, there was no association between estimated research and development investments and treatment costs based on list prices at the launch of the product or based on net prices a year after launch. Findings of this study suggest drug companies should make further data available if they want to use this argument to justify high prices.
Authors: Olivier J. Wouters, Ph.D., of the London School of Economics and Political Science, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.18623)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.18623?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092622
About JAMA Network Open : JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open